West Pharmaceutical Services, Inc. Common Stock (WST)
309.69
+32.69 (11.80%)
NYSE · Last Trade: Oct 23rd, 10:42 AM EDT
Detailed Quote
Previous Close
277.00
Open
301.06
Bid
309.69
Ask
311.31
Day's Range
300.00 - 322.34
52 Week Range
187.43 - 352.33
Volume
537,033
Market Cap
22.39B
PE Ratio (TTM)
46.36
EPS (TTM)
6.7
Dividend & Yield
0.8400 (0.27%)
1 Month Average Volume
646,502
Chart
About West Pharmaceutical Services, Inc. Common Stock (WST)
West Pharmaceutical Services is a prominent global leader in the design and manufacturing of components and systems for the delivery of injectable drugs. The company specializes in producing high-quality materials such as stoppers, seals, and prefillable syringes, which are essential for the safe and efficient administration of pharmaceuticals. West Pharmaceutical Services partners with pharmaceutical and biotechnology companies to deliver innovative solutions that enhance drug efficacy and patient safety, focusing on advancing healthcare through its cutting-edge technologies and services. With a commitment to excellence and a strong emphasis on sustainability, West continually strives to improve the standards of drug delivery within the healthcare industry. Read More
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the S&P500 top gainers and losers shaping the early market sentiment.
West Pharmaceutical Services (WST) beats Q3 2025 earnings and revenue estimates, raises full-year guidance. The strong results, led by an EPS beat, sent the stock up over 6% pre-market.
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 7.7% year on year to $804.6 million. The company’s full-year revenue guidance of $3.07 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $1.96 per share was 16.3% above analysts’ consensus estimates.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently -
over the past six months, the collective 8.4% gain for healthcare stocks has fallen short of the S&P 500’s 22.7% rise.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In West Pharmaceuticals (WST) To Contact Him Directly To Discuss Their Options
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at drug development inputs & services stocks, starting with Medpace (NASDAQ:MEDP).
West Pharmaceutical Services has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 16.3% to $260.31 per share while the index has gained 18.6%.
In a significant shift that has caught the attention of financial markets and online communities alike, Bill Gates, through his investment vehicle Cascade Investment, has made notable adjustments to his extensive portfolio. The most prominent move, widely discussed on platforms like Reddit, involves a substantial increase in his stake in
West Pharmaceutical Servs's (NYSE: WST) short interest as a percent of float has risen 9.25% since its last report. According to exchange reported data, there are now 1.68 million shares sold short, which is 3.07% of all regular shares that are available for trading.
Shares of healthcare products company West Pharmaceutical Services (NYSE:WST)
jumped 3.1% in the afternoon session after a research note from KeyBanc Capital Markets indicated positive momentum in the bioprocessing sector following an industry conference.
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the life sciences tools & services industry, including PacBio (NASDAQ:PACB) and its peers.
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.
Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the life sciences tools & services industry, including Illumina (NASDAQ:ILMN) and its peers.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the life sciences tools & services stocks, including 10x Genomics (NASDAQ:TXG) and its peers.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at drug development inputs & services stocks, starting with West Pharmaceutical Services (NYSE:WST).
